JP2015528798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528798A5 JP2015528798A5 JP2015519357A JP2015519357A JP2015528798A5 JP 2015528798 A5 JP2015528798 A5 JP 2015528798A5 JP 2015519357 A JP2015519357 A JP 2015519357A JP 2015519357 A JP2015519357 A JP 2015519357A JP 2015528798 A5 JP2015528798 A5 JP 2015528798A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- phenyl
- ray powder
- powder diffraction
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 4
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 238000002329 infrared spectrum Methods 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- -1 4-aminomethyl-benzylcarbamoyl Chemical group 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- DHNSEQGWKLRFOE-XJEPUKKESA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide;hydrochloride Chemical compound Cl.C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 DHNSEQGWKLRFOE-XJEPUKKESA-N 0.000 claims 2
- 239000011877 solvent mixture Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668543P | 2012-07-06 | 2012-07-06 | |
| GB1212081.2 | 2012-07-06 | ||
| US61/668,543 | 2012-07-06 | ||
| GB201212081A GB201212081D0 (en) | 2012-07-06 | 2012-07-06 | New polymorph |
| PCT/GB2013/051781 WO2014006414A1 (en) | 2012-07-06 | 2013-07-05 | Polymorphs of|n-[(r)-1 -[(s)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoy l]-2-(4-e|thoxy-phenyl)-ethyl]-benzamide hydrochloride |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528798A JP2015528798A (ja) | 2015-10-01 |
| JP2015528798A5 true JP2015528798A5 (enExample) | 2016-08-12 |
| JP6367187B2 JP6367187B2 (ja) | 2018-08-01 |
Family
ID=46766283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519357A Expired - Fee Related JP6367187B2 (ja) | 2012-07-06 | 2013-07-05 | Ｎ−［（ｒ）−１−［（ｓ）−１−（４−アミノメチル−ベンジルカルバモイル）−２−フェニルエチルカルバモイル］−２−（４−エトキシ−フェニル）−エチル］−ベンズアミド塩酸塩の多形体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9512065B2 (enExample) |
| EP (1) | EP2870137B8 (enExample) |
| JP (1) | JP6367187B2 (enExample) |
| CA (1) | CA2878319C (enExample) |
| ES (1) | ES2679370T3 (enExample) |
| GB (1) | GB201212081D0 (enExample) |
| HU (1) | HUE039775T2 (enExample) |
| PL (1) | PL2870137T3 (enExample) |
| TR (1) | TR201809681T4 (enExample) |
| WO (1) | WO2014006414A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2510407A (en) * | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| JP2019507746A (ja) | 2016-03-10 | 2019-03-22 | オクシュリオン エヌブイ | 胎盤増殖因子のアンタゴナイズによる後眼部線維症の阻害 |
| WO2017207983A1 (en) | 2016-05-31 | 2017-12-07 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| JP2020506916A (ja) | 2017-01-30 | 2020-03-05 | ヤンセン バイオテツク，インコーポレーテツド | 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法 |
| EP3579871A4 (en) | 2017-02-07 | 2021-07-21 | Janssen Biotech, Inc. | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS OF TREATMENT FOR ACTIVE BECHTEREW'S LIVER |
| JP7078722B2 (ja) | 2017-11-29 | 2022-05-31 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤を含む剤形 |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
| MX2022014430A (es) | 2020-05-21 | 2023-02-22 | Janssen Biotech Inc | Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa. |
| AU2022233254A1 (en) | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| IT1223401B (it) * | 1987-12-02 | 1990-09-19 | Montedison Spa | Poliesteri aromatici liquido cristallini termotropici |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| ZA951617B (en) * | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
| US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
| EP1364960A4 (en) * | 2001-02-02 | 2005-05-18 | Chugai Pharmaceutical Co Ltd | PEPTIDE DERIVATIVES |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| DE10301300B4 (de) * | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005095328A1 (en) * | 2004-04-02 | 2005-10-13 | Glaxo Group Limited | Chemical process and new crystalline form |
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| CA2588724A1 (en) * | 2004-11-30 | 2006-06-08 | Mallinckrodt Inc. | Crystallization method for benzphetamine |
| EP1981854B1 (en) * | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| DE102006050672A1 (de) * | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| CA2783801A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| AU2011210802B2 (en) * | 2010-01-28 | 2014-10-16 | The Medicines Company (Leipzig) Gmbh | Trypsin-like serine protease inhibitors, and their preparation and use |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| GB2494851A (en) * | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
-
2012
- 2012-07-06 GB GB201212081A patent/GB201212081D0/en not_active Ceased
-
2013
- 2013-07-05 CA CA2878319A patent/CA2878319C/en active Active
- 2013-07-05 TR TR2018/09681T patent/TR201809681T4/tr unknown
- 2013-07-05 WO PCT/GB2013/051781 patent/WO2014006414A1/en not_active Ceased
- 2013-07-05 JP JP2015519357A patent/JP6367187B2/ja not_active Expired - Fee Related
- 2013-07-05 PL PL13737357T patent/PL2870137T3/pl unknown
- 2013-07-05 EP EP13737357.7A patent/EP2870137B8/en active Active
- 2013-07-05 US US14/413,086 patent/US9512065B2/en not_active Expired - Fee Related
- 2013-07-05 HU HUE13737357A patent/HUE039775T2/hu unknown
- 2013-07-05 ES ES13737357.7T patent/ES2679370T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517463A5 (enExample) | ||
| JP2019517464A5 (enExample) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| HRP20221019T1 (hr) | Polimorfi od n-[(3-fluoro-4-metoksipiridin-2-il)metil]-3-(metoksimetil)-1-({4-[2-oksopiridin-1-il)metil]fenil}metil)pirazol-4-karboksamida kao kalikrein inhibitori | |
| JP2021504310A5 (enExample) | ||
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| HRP20201131T1 (hr) | Derivati pirazola kao inhibitori kalikreina plazme | |
| CY1121751T1 (el) | Αμιδο-υποκατεστημενα ινδαζολια ως αναστολεις πολυμερασης πολυ(αdρ-ριβοζης)(parp) | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| JP2011523412A5 (enExample) | ||
| JP2015078220A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| FI3811943T3 (fi) | Yhdiste käytettäväksi silmäsairauksien hoidossa | |
| NO20083562L (no) | Cannabinoidreseptormodulatorer | |
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| WO2015184011A3 (en) | Agonists of the apelin receptor and methods of use thereof | |
| JP2014506582A5 (enExample) | ||
| JP2016530262A5 (enExample) | ||
| JP2009541216A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2016523260A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JP2015503579A5 (enExample) |